Cell line · CVCL_0026
Papers111
1 more article gives this line's RRID in its Methods without naming the line nearby, so it is not listed.
1 to 20 of 111
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Activation of PP2A-B56a leads to aberrant EGFR signaling and proliferative phenotypes in PDAC. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The CD49b (ITGA2) collagen receptor excludes CD8+ T cell infiltration in pancreatic ductal adenocarcinoma. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Early induction of the Rho-GEF ECT2 drives MEK/ERK oncogenic signaling in pancreatic ductal adenocarcinoma. | Oncogene | 2026 | Its Methods give the RRID and name the line | PubMed | |
| ERO1L induces macrophage infiltration to potentiate KrasG12D and inflammation-induced pancreatic tumorigenesis via oxidative protein folding of CCL2. | Cell Biosci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Mutant KRAS promotes NF-κB driven CCL20 chemokine expression in pancreatic ductal adenocarcinoma. | bioRxiv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting HAS2 to enhance anti-tumor immunity in pancreatic cancer via PD-L1 regulation. | Commun Biol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The Effect of AZD5153 on Radiosensitivity in Pancreatic Cancer Cells Through ATM-chk1 Pathway. | Drug Des Devel Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Extracellular matrix sensing regulates intratumoral heterogeneity of autophagic flux. | Cell | 2026 | Its Methods give the RRID and name the line | PubMed | |
| TIPE2 knockdown enhances the anti-tumor efficacy of NKG2D CAR-T cells against pancreatic cancer via activating NF-κb signaling pathway. | J Transl Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Subcellular Redistribution of Endomembrane GPR15 Promotes NAD+-Mediated Metabolic Reprogramming and Boosts 5-FU Chemosensitivity in Colorectal Cancer. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Sym024 Interacts with a Unique Epitope on the CD73 Homodimer, Favoring Effective Bivalent Binding to Improve Anti-PD-1 Therapy. | Clin Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Engineering tandem VHHs to target different epitopes to enhance antibody-dependent cell-mediated cytotoxicity. | FEBS Open Bio | 2026 | Its Methods give the RRID and name the line | PubMed | |
| DS-3939a: A TA-MUC1-Directed Antibody-Drug Conjugate with Broad Antitumor Activity. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Simultaneous targeting of KRAS and CDK4 synergistically induces durable growth arrest in pancreatic cancer cells. | Cell Death Dis | 2025 | Its Methods give the RRID and name the line | PubMed | |
| KLF5 enables dichotomous lineage programs in pancreatic cancer via the AAA+ ATPase coactivators RUVBL1 and RUVBL2. | Nat Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| DUSP6 is upregulated in metastasis and influences migration and metabolism in pancreatic cancer cells. | Sci Rep | 2025 | Its Methods give the RRID and name the line | PubMed | |
| SP1-Mediated Glycolytic Reprogramming Promotes Tumorigenesis and Progression in Pancreatic Cancer. | Adv Sci (Weinh) | 2025 | Its Methods give the RRID and name the line | PubMed | |
| A first-in-class EGFR-directed KRAS G12V selective inhibitor. | Cancer Cell | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Stromal Hedgehog Signaling Is Associated with Favorable Outcomes in Pancreatic Cancer. | Int J Mol Sci | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Therapeutic applications of a novel humanized monoclonal antibody targeting chemokine receptor CCR9 in pancreatic cancer. | Mol Oncol | 2025 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0026/papers